• In vitro or in vivo bioassays, including model systems that have meaningful short-to medium-term endpoints with respect to human diseases or that are otherwise relevant to predicting human disease outcomes may be useful potential screening tools. These should be used with caution and cannot be considered substitutes for clinical studies.
• Careful consideration of matrix effects on active ingredients and in subsequent studies of bioavailability of active ingredients should be used. The focus of this concern is the potential problems in interpretation of studies of active ingredients in their natural milieu versus those that have been isolated and/or synthesized. The discussants concluded that the process by which active ingredients in dietary supplements are identified needs to developed with attention paid to the following caveats:
• Both chemical and biological characterizations of dietary supplements are needed. To accomplish this, investigators must recognize that analytical chemistry of active ingredients depends upon the chemical identification of numerous specific components of complex mixtures. For example, within soybeans, there are three major soybean isoflavones, daidzein, genistein and glycitein, each of which can exist as an aglycone, a glycoside or acetylated or malonated glycosides. Soybeans also contain at least 16 phenolic acids and several forms of saponins, just to name a few of the major classes of nonnutrient components present in these foods. The group agreed that the identification of meaningful components was key. Meaningful was defined as "components that produce a biological effect." It was generally agreed that identification of meaningful components should precede study of their bioavailability.
• With specific regard to botanically derived supplements, the central question posed was: "Are traditional nutritional and pharmacological approaches applicable to herbal supplements?" The discussants agreed that in general such approaches would apply. However, the group provided the following caveat: the approaches would need to be technically sophisticated enough to recognize multiple biologically active substances in products, with the likelihood of multiple biological activity endpoints.
• Standards are an essential component for the analyses of active ingredients. Usually the most accurate methods for compound detection are relatively expensive and slow, involving complex and tedious extraction procedures. The methods depend upon the production and identification of standards. Standards may vary in stability and detectability. For example, soybean saponins may be detected by the presence of a moiety, 2,3-dihydro-2,5-di-hydroxy-6-methyl-4H-pyran-4H-1, which is heat labile. The remaining compound has much less ultraviolet absorbance than do 2,3-dihydro-2,5-dihydroxy-6-methyl-4H-pyran-4H-1-containing saponins. Methods may be facilitated by development of appropriate internal standards, but it is not always a straightforward task to find or develop stable inexpensive internal standards that are not present in the product to be assayed. Potential interactions among components must be considered. Such interactions might cause a component to in effect appear or disappear, depending upon conditions. Ultimately, development and maintenance of databases containing analytical information is desirable.
• Sampling strategies should be developed to identify and use the most commonly used products. Product formulations will be likely to change as knowledge of biological efficacy develops. Analytical methods may also become more sophisticated as the knowledge base grows. Therefore, continual maintenance and upgrade of databases are critical. An example of a relevant database is a soybean isoflavone database developed by scientists at the Nutrient Composition Laboratory (U.S. Department of Agriculture, Agricultural Research Services, Beltsville, MD) and Iowa State University (Available at: http://www.nal.usda.gov/fnic/foodcomp/ data/isoflav/isoflav.html).
• Bioavailability studies. The discussants identified a number of issues to be considered in this context including: 1. Although the active ingredients may exist in several forms, such as the soybean isoflavones, the relative bioavailability of all active forms needs to be estimated. 2. Because it would be unusual for active ingredients not to undergo biotransformation, bioavailability studies must include the identification and analysis of the metabolites of active ingredient. These metabolites may be of greater or lesser bioactivity than are the parent compounds. 3. Doses, dosing interval and duration need to be determined, based on common or recommended usage. 4. Because bioavailability of presumably active ingredients may change with time, adaptive responses should be anticipated. 5. Bioavailability may be affected by interactions with other ingredients or with other dietary components. 6. Physiological state could also influence bioavailability (e.g., gender, ethnicity, age, health status) and, therefore, must be included in such states.
